Funding | BEAM Alliance

Funding

PUBLIC GRANTS, PUBLIC FUNDING INSTRUMENTS OR NON PROFIT COLLABORATIONS

CARB-X

World: CARB-X, Combating Antibiotic Resistant Bacteria

SCOPE: CARB-X welcomes applications from around the world for funding and support for the early development of antibiotics, diagnostics, vaccines, devices and other products to combat the most serious drug-resistant bacteria.

KEY DATES & APPLICATION: CARB-X 2018 Funding Round 2 is now closed. The next round of funding will be announced in the coming months.

More information available here

NEWS: May 22, 2018: UK GOVERNMENT AND BILL & MELINDA GATES FOUNDATION JOIN CARB-X PARTNERSHIP IN FIGHT AGAINST SUPERBUGS

FRENCH-GERMAN CALL FOR PROJECTS ON ANTIMICROBIAL RESISTANCE 2019

EU: FRENCH-GERMAN CALL FOR PROJECTS ON ANTIMICROBIAL RESISTANCE 2019

SCOPE: The French Ministry of Higher Education, Reseearch and Innovation (MESRI) and the Germand Federal Ministry of Education and Research (BMBF) intend to enable French and German scientists to build an effective collaboration on a common reserach project within the field of AMR in human infections, implicating multiple research domains. Unmet needs within this field have been prioritized to gain knowledge, which could then be implemented into current public health policies of appropriate products to tackle AMR.

KEY DATES & APPLICATION: 
February 27, 2019, 1pm (CET): Submission of proposals on the ANR site 
Summer 2019: Notification of results by ANR and VDI/VDE-IT 
Earliest possible start date: End of 2019

More information available here

InnovFin Infectious Diseases

EU: InnovFin Infectious Diseases (IDFF)

SCOPE: The InnovFin Infectious Diseases Finance Facility (IDFF) provides financial products ranging from standard debt to equity-type financing for amounts typically between EUR 7.5 million and EUR 75 million, to innovative players active in developing innovative vaccines, drugs, medical and diagnostic devices or novel research infrastructures for combatting infectious diseases. Project costs may include clinical trial costs, set-up of commercialisation such as market access, development of prototypes or industrial roll-out of novel equipment, pre-clinical R&D costs and working capital requirement. The product is being made available directly through the European Investment Bank.

KEY DATES & APPLICATION: See here

More information available here

Horizon2020 SME Instrument

EU: Horizon2020 SME Instrument

SCOPE: The SME Instrument supports high-risk, high-potential small and medium-sized enterprises to develop and bring to market new products, services and business models that could drive economic growth. The SME Instrument is for innovators with ground-breaking concepts that could shape new markets or disrupt existing ones in Europe and worldwide.

The SME Instrument provides full-cycle business innovation support. It has three phases, including a coaching service.
1. Feasibility study: Phase 1
2. From concept to market: Phase 2
3. Commercialisation: Phase 3

KEY DATES & APPLICATION: 
Opening date: 7 November 2017
Cut-off dates: Multiple (until oct/nov 2020)

More information available here

DRIVe BARDA initiative / DRIVe-X

World: DRIVe BARDA initiative / DRIVe-X

SCOPE: The Biomedical Advanced Research and Development Authority (BARDA) serves the US nation by partnering with industry to make available medical countermeasures against wide range of major threats to the health security. DRIVe (Division of Research, Innovation, and Ventures) is a bold new approach to achieving once-unthinkable solutions to health security challenges – through the power of collaboration and innovation. DRIVe PPP will provide non-dilutive and dilutive funding opportunities to Companies (DRIVe-X), VCs (Ventures V), non-for-profit third parties (LAUNCH) and regional accelerators (ACCELERATORS).

3 KEY FOCUS AREAS: 
SEPSIS: new technologies to aid in restoring patients’ homeostasis. 

ENACT (Early Notification to Act, Control and Treat): closing the gap between diagnosis and treatment by leveraging advanced data analytics and algorithms coupled with innovative detection modalities. 

Other areas: creating universal treatment options for broad classes of pathogens, ensuring access to life-saving medical countermeasures, and transforming medical countermeasure development by eradicating animal testing (non-exhaustive).

More information available here

DRIVe EZ-BAA Notice details available here

INVESTORS

Novo REPAIR Impact fund

World: Novo REPAIR Impact fund

SCOPE: The REPAIR (Replenishing and Enabling the Pipeline for Anti-Infective Resistance) Impact Fund will invest in start-ups, early-stage companies and corporate spin-outs in Europe and the United States. Their philosophy is to support ambitious programmes addressing antimicrobial resistance through a broad range of therapeutic modalities. The fund will focus on priority pathogens as defined by the World Health Organization and the United States Centers for Disease Control and Prevention, a catalogue of 12 families of bacteria that pose the greatest threat to human health. The fund is expected to invest USD 20 million to 40 million per year over 3–5 years in about 20 projects in Europe and the United States, which is anticipated to yield at least one new therapy reaching the market.

KEY DATES & APPLICATION: The first round of investments dedicated to European companies will start in April 2018 and non-confidential presentations can be sent until 15 May 2018. The first investments are expected by the end of 2018. A second round of investments focusing on United States companies will start in the fall 2018. Novo’s REPAIR Impact fund will re-open for proposals during the window 4 Sep – 11 Oct.

More information available here